The estimated Net Worth of John M Siebert is at least $2.72 Миллион dollars as of 11 August 2021. John Siebert owns over 15,000 units of Supernus Pharmaceuticals Inc stock worth over $2,360,619 and over the last 13 years he sold SUPN stock worth over $0. In addition, he makes $357,453 as Independent Director at Supernus Pharmaceuticals Inc.
John has made over 10 trades of the Supernus Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of SUPN stock worth $194,700 on 11 August 2021.
The largest trade he's ever made was exercising 16,179 units of Supernus Pharmaceuticals Inc stock on 20 August 2018 worth over $137,845. On average, John trades about 2,358 units every 113 days since 2012. As of 11 August 2021 he still owns at least 75,953 units of Supernus Pharmaceuticals Inc stock.
You can see the complete history of John Siebert stock trades at the bottom of the page.
Dr. John M. Siebert Ph.D. serves as Independent Director of the Company. Dr. Siebert is currently Acting Principal Executive Officer of Aradigm Corporation, a publicly traded respiratory pharmaceuticals development company. Dr. Siebert was appointed to this position in February 2018 in connection with the resignation of Aradigm's executive officers. Upon his appointment, Dr. Siebert resigned from Aradigm's board of directors, where he served as chairman. Dr. Siebert is Founder and CEO of Compan Pharmaceuticals, a companion animal pharmaceutical company developing a drug to treat transitional cell cancer. He is a member of the board of directors of Riverside Pharmaceuticals. From May 2014 to November 2015, Dr. Siebert was Chief Executive Officer of Chase Pharmaceuticals, a company conducting clinical trials in Alzheimer's disease based on a unique hypothesis. From 2010 to 2014, he was a Partner and Chief Operating Officer of New Rhein Healthcare Investors, LLC, a private equity group. From May 2003 to October 2008, Dr. Siebert was the chairman and Chief Executive Officer of CyDex, Inc., a privately held specialty pharmaceutical company. From September 1995 to April 2003, he was President and Chief Executive Officer of CIMA Labs Inc., a publicly traded specialty pharmaceutical company, and from July 1995 to September 1995 he was President and Chief Operating Officer of CIMA Labs. From 1992 to 1995, Dr. Siebert was Vice President, Technical Affairs at Dey Laboratories, Inc., a privately held pharmaceutical company. From 1988 to 1992, he headed R&D and Quality Control at a division of Bayer Corporation. Prior to that, Dr. Siebert was employed by E.R. Squibb & Sons, Inc., G.D. Searle & Co., Gillette and The Procter & Gamble Company. Dr. Siebert holds a B.S. in Chemistry from Illinois Benedictine University, an M.S. in Organic Chemistry from Wichita State University and a Ph.D. in Organic Chemistry from the University of Missouri.
As the Independent Director of Supernus Pharmaceuticals Inc, the total compensation of John Siebert at Supernus Pharmaceuticals Inc is $357,453. There are 9 executives at Supernus Pharmaceuticals Inc getting paid more, with Jack Khattar having the highest compensation of $8,123,130.
John Siebert is 80, he's been the Independent Director of Supernus Pharmaceuticals Inc since 2011. There are no older and 16 younger executives at Supernus Pharmaceuticals Inc.
John's mailing address filed with the SEC is C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE, MD, 20850.
Over the last 13 years, insiders at Supernus Pharmaceuticals Inc have traded over $37,265,765 worth of Supernus Pharmaceuticals Inc stock and bought 16,600,700 units worth $83,216,588 . The most active insiders traders include Forest Baskett, Scott D Sandell и Peter J Barris. On average, Supernus Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $4,263,834. The most recent stock trade was executed by Jack A. Khattar on 3 September 2024, trading 21,000 units of SUPN stock currently worth $652,680.
pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
Supernus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: